Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Taysha Gene Therapies (TSHA) Assets Average (2022 - 2025)

Taysha Gene Therapies' Assets Average history spans 4 years, with the latest figure at $324.9 million for Q3 2025.

  • For Q3 2025, Assets Average rose 70.75% year-over-year to $324.9 million; the TTM value through Sep 2025 reached $324.9 million, up 70.75%, while the annual FY2024 figure was $166.5 million, 11.4% up from the prior year.
  • Assets Average for Q3 2025 was $324.9 million at Taysha Gene Therapies, up from $235.8 million in the prior quarter.
  • Across five years, Assets Average topped out at $324.9 million in Q3 2025 and bottomed at $91.6 million in Q2 2023.
  • The 4-year median for Assets Average is $158.5 million (2022), against an average of $167.0 million.
  • The largest annual shift saw Assets Average crashed 40.6% in 2023 before it soared 92.96% in 2024.
  • A 4-year view of Assets Average shows it stood at $118.9 million in 2022, then surged by 55.0% to $184.2 million in 2023, then decreased by 7.58% to $170.3 million in 2024, then soared by 90.82% to $324.9 million in 2025.
  • Per Business Quant, the three most recent readings for TSHA's Assets Average are $324.9 million (Q3 2025), $235.8 million (Q2 2025), and $149.4 million (Q1 2025).